Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of BT051 in Healthy Subjects
NCT05103878Phase 1Completed
- Sponsor
- Bacainn Therapeutics, Inc.
- Start
- Jun 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ADS051 in ulcerative colitis (UC) (6 arms), sponsored by Bacainn Therapeutics, Inc. Primary endpoints: Treatment-Emergent Adverse Events at Day 30, Clinically Significant Laboratory Changes at Day 30 and 1 more. Started Jun 2020; status: completed.
02
Drugs
ADS051
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05103878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05103878.